gilteritinib
gilteritinib: 12 clinical trials tracked.
gilteritinib evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
What is verified about gilteritinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 6 study sponsors
Clinical Trials (12)showing 10 most recent
Clinical Study of Sonrotoclax Combined With Azacitidine Plus Individualized Targeted Drugs in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia
Primary endpoint: Composite Complete Remission
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Primary endpoint: Safety and adverse events (AEs)
A Comparison Between Gilteritinib in Phase 3 Trials Versus Real-World External Comparator Cohort of Relapsed/Refractory (R/R) FLT3m+ Acute Myeloid Leukemia (AML) Patients After Hematopoietic Stem Cell Transplantation (HSCT)
Primary endpoint: Relapse Free Survival (RFS)
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Primary endpoint: Rate of measured residual disease (MRD) negative complete remission (CR)
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
Primary endpoint: Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia
Primary endpoint: Rate of dose limiting toxicities (DLTs) per dose level
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Primary endpoint: Minimal residual disease (MRD)-negativity rate
A Phase 1 Study of Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated Acute Myeloid Leukemia
Primary endpoint: Maximum Tolerated Dose (MTD)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Primary endpoint: Event-free survival (EFS)
A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Primary endpoint: Recommended Phase 2 Dose (RPTD) of Co-administered Study Drugs